Olivier Christoph B, Middleton Stephanie K, Purington Natasha, Shashidhar Sumana, Hereford Jody, Mahaffey Kenneth W, Turakhia Mintu P
Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Center for Digital Health, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Cardiovasc Digit Health J. 2021 Feb 9;2(2):101-108. doi: 10.1016/j.cvdhj.2021.01.003. eCollection 2021 Apr.
We performed a trial to evaluate the efficacy of a blended intervention with personalized health coaching and virtual cardiac rehabilitation to improve medication adherence and risk factors. The trial was terminated early. Here, we describe findings from a root cause analysis and lessons learned.
SmartGUIDE was an open-label, single-center trial that randomized participants with coronary artery disease who were prescribed a statin and/or P2Y12 inhibitor 1:1 to either usual care or the added use of a mobile app with components of cardiac rehabilitation paired with personal virtual coaching. The primary outcome was medication adherence: proportion of days covered (PDC). The planned sample size was 132. We performed a root cause analysis to evaluate processes from study development to closure.
During trial conduct, the technology start-up withdrew the intervention. The study was terminated early with 63 participants randomized and data from 26 available for analysis. The median PDC was high in both groups (intervention group 94%, interquartile range [IQR] 88%-96%; control group: 99%, IQR 95%-100%). Root cause analysis identified factors for not achieving trial objectives: key factors that limited enrollment (inclusion criteria, low penetration of compatible smartphones), participant retention or engagement (poor app product, insufficient technology support), and suboptimal choice of a technology partner (technology start-up's inexperience in health care, poor product design, inadequate fundraising).
We identified important and preventable factors leading to trial failure. These factors may be common across digital health trials and may explain prior observations that many such trials are never completed. Careful vetting of technology partners and more pragmatic study designs may prevent these missteps.
我们开展了一项试验,以评估个性化健康指导与虚拟心脏康复相结合的综合干预措施在改善药物依从性和风险因素方面的疗效。该试验提前终止。在此,我们描述根本原因分析的结果及经验教训。
SmartGUIDE是一项开放标签、单中心试验,将开具他汀类药物和/或P2Y12抑制剂的冠心病参与者按1:1随机分为常规治疗组或在常规治疗基础上增加使用一款具备心脏康复组件并配有个人虚拟指导的移动应用程序组。主要结局为药物依从性:覆盖天数比例(PDC)。计划样本量为132。我们进行了根本原因分析,以评估从研究开展到结束的各个流程。
在试验进行过程中,技术初创公司撤回了干预措施。该研究提前终止,共有63名参与者被随机分组,其中26名参与者的数据可供分析。两组的PDC中位数均较高(干预组为94%,四分位间距[IQR]为88%-96%;对照组为99%,IQR为95%-100%)。根本原因分析确定了未实现试验目标的因素:限制入组的关键因素(纳入标准、兼容智能手机普及率低)、参与者留存或参与度(应用程序产品不佳、技术支持不足)以及技术合作伙伴的选择欠佳(技术初创公司在医疗保健方面缺乏经验、产品设计不佳、资金筹集不足)。
我们确定了导致试验失败的重要且可预防的因素。这些因素可能在数字健康试验中普遍存在,并可能解释了之前许多此类试验从未完成的现象。对技术合作伙伴进行仔细审查以及采用更务实的研究设计可能会避免这些失误。